Celcuity Inc. (CELC)
Market Closed
24 Feb, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
105. 79
+0.64
+0.61%
$
4.85B Market Cap
- P/E Ratio
- Div Yield
353,457 Volume
- Eps
$ 105.15
Previous Close Day Range
104.5 107.5
Year Range
7.58 120.31
Want to track CELC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CELC earnings report is expected in 22 days (19 Mar 2026)
Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks.
Seekingalpha | 1 year ago
